Novartis-- The U.S. Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm555778.htm